myelodysplastic syndromes
Amneal Receives FDA Approval for Lenalidomide
Amneal Pharmaceuticals Inc. has received approval from the FDA for its Abbreviated New Drug Application for ...
MARCH 5, 2025
Rytelo Approved for Low- to Intermediate-1-Risk MDS With Transfusion-Dependent Anemia
The FDA approved imetelstat (Rytelo, Geron Corp.), an oligonucleotide telomerase inhibitor, for adults with low- to ...
JUNE 10, 2024
New Therapy for MDS-Related Anemia More Effective Than Standard Epoetin Alfa
The novel therapy luspatercept (Reblozyl, Bristol Myers Squibb) was more effective than epoetin alfa for achieving ...
JANUARY 15, 2024
FDA Approves Tibsovo for Myelodysplastic Syndromes
The FDA approved ivosidenib (Tibsovo, Servier Pharmaceuticals) for adult patients with relapsed or refractory ...
OCTOBER 26, 2023
MDS Commonly Misdiagnosed
Does a diagnosis of myelodysplastic syndromes/neoplasms (MDS) need a second opinion? Findings from a new study ...
OCTOBER 18, 2023
Luspatercept Reduces Dependence on Blood Transfusions in Patients With MDS
Treatment with luspatercept (Reblozyl, Bristol Myers Squibb) led to significant improvements in red blood cell ...
AUGUST 23, 2023
Emerging Treatment Options for High-Risk Myelodysplastic Syndromes
During the National Comprehensive Cancer Network (NCCN) 2022 Annual Congress: Hematologic Malignancies, Uma M. ...
DECEMBER 9, 2022
New Biomarker Predicts MDS Treatment Response
Researchers have identified a new biomarker to predict treatment response for myelodysplastic syndromes (MDS), ...
MARCH 22, 2022
Mayo Clinic Researchers Create Gene-Based Prognostic Model for MDS
Researchers from Mayo Clinic have developed a new risk model MDS. The genetics-based prognostic tool replaces a ...
OCTOBER 29, 2018
Understanding Why Some MDS Resists Azacitidine Treatment
Patients with myelodysplastic syndrome who are resistant to azacitidine (AZA) have quiescent bone marrow ...
NOVEMBER 6, 2017
Investigational MAB Granted Orphan Drug Status for MDS
The investigational drug BI 836858 was granted Orphan drug designation for the treatment of MDS.
MARCH 9, 2017
ASH 2016: Guillermo Garcia-Manero, MD, on Promising Clinical Data for MDS
Dr. Garcia-Manero highlighted some of the most promising clinical data presented at the 2016 ASH annual meeting.
JANUARY 24, 2017
